20:41 , Jan 18, 2019 |  BC Week In Review  |  Financial News

Acceleron, Stemline price upsized follow-ons

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch. Acceleron said Jan. 16 that...
20:35 , Jan 18, 2019 |  BC Week In Review  |  Financial News

INmuneBio sets IPO terms

INmuneBio Inc. (La Jolla, Calif.) amended its NASDAQ IPO and now plans to sell between 1 million and 2.5 million shares at $8. At the midpoint of 1.75 million shares, the company would raise $14...
14:50 , Jan 16, 2019 |  BC Extra  |  Financial News

Acceleron, Stemline price upsized follow-ons

Acceleron Pharma Inc. (NASDAQ:XLRN) and Stemline Therapeutics Inc. (NASDAQ:STML) have each priced upsized follow-ons, as one company prepares for key regulatory submissions and the other conducts its first product launch. Acceleron said Wednesday that it...
00:23 , Jan 12, 2019 |  BioCentury  |  Finance

We all fall down

After an exuberant third quarter that put biotech indexes near their 2015 highs, all market cap tiers fell in 4Q18, eliminating the first nine month's gains and losing $291.2 billion in aggregate value. Median losses...
18:12 , Jan 11, 2019 |  BC Week In Review  |  Company News

Takeda divesting $10B in non-core assets following completed Shire acquisition

Takeda Pharmaceutical Co. Ltd. (Tokyo:4502) said Jan. 7 that it completed its acquisition of Shire plc (Dublin, Ireland). At the J.P. Morgan Healthcare Conference on Jan. 8 to discuss the acquisition, Takeda President and CEO...
05:09 , Jan 5, 2019 |  BioCentury  |  Product Development

Bristol-Myers’ next phoenix act?

Bristol-Myers Squibb Co. will now be in the driver’s seat to monetize the assets gained from the myriad deals Celgene Corp. has forged. The pharma will need to mimic its history of using well-timed acquisitions...
02:49 , Jan 5, 2019 |  BioCentury  |  Finance

Ready to launch

  The proposed $74 billion takeout of Celgene Corp. by Bristol-Myers Squibb Co. will not shift buysider attention away from upcoming and maturing drug launches heading into 2019, with plenty to track following a record...
04:16 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Cellid proposes Korean IPO

Cell-based vaccine company Cellid Co. Ltd. (Seoul, South Korea) proposed on Dec. 13 to sell 1.2 million shares at W22,100-W27,000 in a Korean IPO, according to the Korean Stock Exchange's website. At the W24,550 mid-point,...
03:57 , Jan 4, 2019 |  BC Week In Review  |  Financial News

Junshi gains after Hong Kong IPO

Shanghai Junshi Biosciences Co. Ltd. (HKSE:1877) gained HK$4.37 (23%) to HK$23.75 in its first day of trading Dec. 24 after raising HK$3.1 billion ($393.2 million) through the sale of 158.9 million shares at HK$19.38 in...
22:24 , Jan 2, 2019 |  BC Extra  |  Financial News

With shares still sagging, Moderna gets little bump from initial analyst coverage

Despite optimistic price targets in newly initiated sell-side analyst coverage, Moderna Inc. (NASDAQ:MRNA) shares failed to receive a bump on Wednesday, adding $0.06 to $15.33 but continuing to trade well below their IPO price. According...